Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in Iran

References

• Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 2014;83:1022–4.
   PubMed Web of Science ®Google Scholar
• Trapp BD, Nave K-A. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008;31:247–69.
   PubMed Web of Science ®Google Scholar
• Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Managed Care Pharmacy 2009;15:543–55.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528–32.
   PubMed Web of Science ®Google Scholar
• Weinshenker B, Bass B, Rice G, et al. The natural history of multiple sclerosis: a geographically based study I. Clinical course and disability. Brain 1989;112:133–46.
   PubMed Web of Science ®Google Scholar
• Nortvedt M, Riise T. The use of quality of life measures in multiple sclerosis research. Multiple Sclerosis 2003;9:63–72.
   PubMed Web of Science ®Google Scholar
• Turpin K, Carroll L, Cassidy J, Hader W. Deterioration in the health-related quality of life of persons with multiple sclerosis: the possible warning signs. Multiple Sclerosis 2007;13:1038–45.
   PubMed Web of Science ®Google Scholar
• Hermann BP, Vickrey B, Hays RD, et al. A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res 1996;25:113–8.
   PubMed Web of Science ®Google Scholar
• Riazi A, Hobart J, Lamping D, et al. Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles. J Neurol Neurosur Psychiatry 2003;74:710–4.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Miller D, Clough JD, et al. Quality of life in multiple sclerosis: comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992;49:1237–1242.
   PubMed Web of Science ®Google Scholar
• Ebers GC. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. The Lancet 1998;352:1498–1504.
   PubMed Web of Science ®Google Scholar
• Group IMSS. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655–61.
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285–94.
   PubMed Web of Science ®Google Scholar
• Paty D, Li DB. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662–7.
   PubMed Web of Science ®Google Scholar
• Rothwell P. Quality of life in multiple sclerosis. J Neurol Neurosur Psychiatry 1998;65:433.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Zorzon M, Tommasi MA, et al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci 2003;216:113–8.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005;58:840–6.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis an expanded disability status scale (EDSS). Neurology 1983;33:1444–52.
   PubMed Web of Science ®Google Scholar
• Schwartz CE, Coulthard-Morris L, Cole B, Vollmer T. The quality-of-life effects of interferon beta-1b in multiple sclerosis: an extended Q-TWIST analysis. Arch Neurol 1997;54:1475–80.
   PubMed Web of Science ®Google Scholar
• Arnoldus JH, Killestein J, Pfennings LE, et al. Quality of life during the first 6 months of interferon-B treatment in patients with MS. Multiple Sclerosis 2000;6:338–42.
   PubMed Web of Science ®Google Scholar
• Vermersch P, De Seze J, Delisse B, et al. Quality of life in multiple sclerosis: influence of interferon-β1a (Avonex®) treatment. Multiple Sclerosis 2002;8:377–81.
   PubMed Web of Science ®Google Scholar
• Miller D, Weinstock-Guttman B, Bourdette D, et al. Change in quality of life in patients with relapsing–remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon β-1a. Multiple Sclerosis J 2011;17:734–742.
   PubMed Web of Science ®Google Scholar
• Simone IL, Ceccarelli A, Tortorella C, et al. Influence of Interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes 2006;4:1–7.
   PubMed Web of Science ®Google Scholar
• Auty A, Belanger C, Bouchard J, et al. Burden of illness of multiple sclerosis: part II: quality of life. Can J Neurol Sci 1998;25:31–8.
   PubMed Web of Science ®Google Scholar
• Isaksson A-K, Ahlström G, Gunnarsson L-G. Quality of life and impairment in patients with multiple sclerosis. J Neurol Neurosur Psychiatry 2005;76:64–9.
   PubMed Web of Science ®Google Scholar
• Vickrey B, Hays RD, Harooni R, et al. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995;4:187–206.
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–108.
   PubMed Web of Science ®Google Scholar
• Freeman J, Hobart J, Langdon D, Thompson A. Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosur Psychiatry 2000;68:150–6.
   PubMed Web of Science ®Google Scholar
• Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life in multiple sclerosis measuring the disease effects more broadly. Neurology 1999;53:1098–103.
   PubMed Web of Science ®Google Scholar
• Hobart J, Freeman J, Lamping D, et al. The SF-36 in multiple sclerosis: why basic assumptions must be tested. J Neurol Neurosur Psychiatry 2001;71:363–70.
   PubMed Web of Science ®Google Scholar